Trial Profile
Immunogenicity of a trivalent influenza virus vaccine comprised of recombinant haemagglutinin proteins (FluBlOk) in the elderly
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Protein Sciences Corporation
- 05 Nov 2010 New trial record.